CN101384568B - 乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用 - Google Patents

乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用 Download PDF

Info

Publication number
CN101384568B
CN101384568B CN2007800056683A CN200780005668A CN101384568B CN 101384568 B CN101384568 B CN 101384568B CN 2007800056683 A CN2007800056683 A CN 2007800056683A CN 200780005668 A CN200780005668 A CN 200780005668A CN 101384568 B CN101384568 B CN 101384568B
Authority
CN
China
Prior art keywords
formula
alkyl
hydrogen
phenyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800056683A
Other languages
English (en)
Chinese (zh)
Other versions
CN101384568A (zh
Inventor
Y·G·古
X·徐
M·韦茨伯格
H·沈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CN101384568A publication Critical patent/CN101384568A/zh
Application granted granted Critical
Publication of CN101384568B publication Critical patent/CN101384568B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2007800056683A 2006-02-15 2007-02-15 乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用 Expired - Fee Related CN101384568B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77351406P 2006-02-15 2006-02-15
US60/773,514 2006-02-15
PCT/US2007/062181 WO2007095603A2 (en) 2006-02-15 2007-02-15 Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome

Publications (2)

Publication Number Publication Date
CN101384568A CN101384568A (zh) 2009-03-11
CN101384568B true CN101384568B (zh) 2012-12-12

Family

ID=38330470

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800056683A Expired - Fee Related CN101384568B (zh) 2006-02-15 2007-02-15 乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用

Country Status (6)

Country Link
US (1) US8735595B2 (https=)
EP (1) EP1991536A2 (https=)
JP (1) JP2009526868A (https=)
CN (1) CN101384568B (https=)
CA (1) CA2641766A1 (https=)
WO (1) WO2007095603A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ563866A (en) 2005-05-09 2011-03-31 Achillion Pharmaceuticals Inc Thiazole compounds and methods of use
US8748627B2 (en) * 2006-02-15 2014-06-10 Abbvie Inc. Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
US8183263B2 (en) 2007-05-22 2012-05-22 Achillion Pharmaceuticals, Inc. Heteroaryl substituted thiazoles
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009144554A1 (en) 2008-05-28 2009-12-03 Pfizer, Inc. Pyrazolospiroketone acetyl-c0a carboxylase inhibitors
US8106209B2 (en) 2008-06-06 2012-01-31 Achillion Pharmaceuticals, Inc. Substituted aminothiazole prodrugs of compounds with anti-HCV activity
WO2011058474A1 (en) 2009-11-10 2011-05-19 Pfizer Inc. N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
HRP20161178T1 (hr) 2010-09-30 2016-11-04 Pfizer Inc. N1-PIRAZOLOSPIROKETONSKI INHIBITORI ACETIL-CoA-KARBOKSILAZE
BR112013010310A2 (pt) 2010-10-29 2016-11-29 Pfizer inibidores de acetil-coa carboxilase de lactama n1/n2
MY162167A (en) 2011-04-22 2017-05-31 Pfizer Substituted acetyl-coa carboxylase inhibitors
AU2014262547A1 (en) 2013-05-10 2015-11-26 Gilead Apollo, Llc ACC inhibitors and uses thereof
EA201591959A1 (ru) * 2013-05-10 2016-03-31 Нимбус Аполло, Инк. Ингибиторы акк и их применение
MX2015015422A (es) * 2013-05-10 2016-06-21 Nimbus Apollo Inc Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
SG11201509186TA (en) 2013-06-27 2016-01-28 Pfizer Heteroaromatic compounds and their use as dopamine d1 ligands
HK1217448A1 (zh) 2013-09-12 2017-01-13 辉瑞大药厂 乙酰辅酶a羧化酶抑制剂用於治疗寻常痤疮的用途
EP3670496A3 (en) 2013-10-17 2020-09-30 Shionogi&Co., Ltd. Acc2 inhibitors
JP2016079168A (ja) 2014-10-17 2016-05-16 塩野義製薬株式会社 ９員縮合環誘導体
WO2016084816A1 (ja) * 2014-11-26 2016-06-02 武田薬品工業株式会社 二環性化合物
US10252997B2 (en) 2015-03-31 2019-04-09 Takeda Pharmaceutical Company Limited Monocyclic compound

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59196876A (ja) 1983-04-22 1984-11-08 Sumitomo Chem Co Ltd １，２，４−オキサジアゾ−ル誘導体、その製造法およびそれを有効成分とする除草剤
WO1986003203A1 (fr) * 1984-11-22 1986-06-05 Yoshitomi Pharmaceutical Industries, Ltd. Derives de thienylthiazole
CA2044533A1 (en) * 1990-06-29 1991-12-30 Philippe Guerry Substituted aminoalkylbiphenyl derivatives
WO1995032963A1 (en) * 1994-06-01 1995-12-07 Yoshitomi Pharmaceutical Industries, Ltd. Thienylazole compound and thienotriazolodiazepine compound
AU3087195A (en) 1994-08-02 1996-03-04 Nippon Soda Co., Ltd. Oxazole derivative, process for producing the same, and herbicide
AU3264695A (en) * 1994-08-23 1996-03-14 Nissan Chemical Industries Ltd. Pyridine derivative
DE19536809A1 (de) 1995-10-02 1997-04-03 Basf Ag Heterocyclisch substituierte Salicylsäurederivate
CA2190699A1 (en) * 1995-12-08 1997-06-09 Johannes Aebi Tertiary amines
WO1997025319A1 (en) * 1996-01-05 1997-07-17 Novartis Ag Substituted 1,2,4,6-thiatriazines useful as herbicides
US6268308B1 (en) 1996-08-27 2001-07-31 Syngenta Crop Protection, Inc. Herbicidal S-substituted 1,2,4,6-thiatriazines
JPH11171848A (ja) * 1997-09-26 1999-06-29 Fujirebio Inc 芳香族アミド誘導体
UA71971C2 (en) * 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
AU2001249670A1 (en) * 2000-04-03 2001-10-15 3-Dimensional Pharmaceuticals, Inc. Substituted thiazoles and the use thereof as inhibitors of plasminogen activatorinhibitor-1
US20030171399A1 (en) * 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
JP2004523225A (ja) 2000-12-26 2004-08-05 リサーチ　ディベロップメント　ファンデーション 脂肪燃焼、脂肪蓄積、エネルギーホメオスタシス及びインシュリン作用の調節を標的とするアセチルコエンザイムａカルボキシラーゼ２
EA200400011A1 (ru) 2001-06-07 2004-06-24 Эли Лилли Энд Компани Модуляторы рецепторов, активируемых пролифераторами пероксисом (prar)
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
KR100979988B1 (ko) * 2001-08-13 2010-09-03 얀센 파마슈티카 엔.브이. 2-아미노-4,5-삼치환 티아졸릴 유도체
WO2003026661A1 (fr) * 2001-09-14 2003-04-03 Yamanouchi Pharmaceutical Co., Ltd. Accelerateur de secretion de l'insuline et nouveau derive de pyrimidine
JP2005162612A (ja) * 2002-01-09 2005-06-23 Ajinomoto Co Inc アシルスルホンアミド誘導体
ES2290439T3 (es) 2002-02-25 2008-02-16 Eli Lilly And Company Moduladores del receptor activado del proliferador de peroxisomas.
NZ534582A (en) * 2002-02-27 2006-03-31 Pfizer Prod Inc ACC inhibitors
RU2005121907A (ru) * 2002-12-12 2006-02-27 Галдерма Ресерч Энд Девелопмент, С.Н.С. (Fr) Новые соединения, являющиеся модуляторами рецепторов типа pparгамма, и их применение в косметических или фармацевтических композициях
JP2005272476A (ja) * 2003-04-09 2005-10-06 Japan Tobacco Inc 複素芳香５員環化合物及びその医薬用途
MXPA05010945A (es) 2003-04-09 2005-11-25 Japan Tobacco Inc Compuesto pentaciclico heteroaromatico y uso medicinal del mismo.
MXPA05012679A (es) 2003-05-27 2006-02-08 Sod Conseils Rech Applic Nuevos derivados de imidazoles, su preparacion y su uso como medicamento.
CA2529154C (en) 2003-06-20 2013-05-07 Galderma Research & Development, S.N.C. Novel compounds that modulate ppar.gamma. type receptors, and use thereof in cosmetic or pharmaceutical compositions
GB2404855A (en) 2003-07-07 2005-02-16 Pantherix Ltd Arylcarboxylic acid derivatives and their therapeutic use
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
EP1648875A1 (en) * 2003-07-30 2006-04-26 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
JP2007504229A (ja) * 2003-09-02 2007-03-01 メルク　エンド　カムパニー　インコーポレーテッド 代謝調節型グルタミン酸受容体−５のモジュレーターとしてのビピリジルアミン類およびエーテル類
CA2543707A1 (en) 2003-10-31 2005-05-19 Takeda Pharmaceutical Company Limited Nitrogen-containing fused heterocyclic compounds
WO2005051945A1 (en) 2003-11-20 2005-06-09 Eli Lilly And Company Heterocyclic compounds as modulators of peroxisome proliferator activated receptors, useful for the treatment and/or prevention of disorders modulated by a ppar
WO2005058876A1 (en) * 2003-12-16 2005-06-30 Gpc Biotech Ag Pyrazine derivatives as effective compounds against infectious diseases
AU2004309271A1 (en) * 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
US7470712B2 (en) 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
WO2005113069A2 (en) 2004-05-14 2005-12-01 Research Development Foundation Use of circumin and analogues as inhibitors of acc2
KR101195801B1 (ko) 2004-06-18 2012-11-05 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｘａ 인자 억제제
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
JP2006022065A (ja) 2004-07-09 2006-01-26 Dai Ichi Seiyaku Co Ltd カルバメート誘導体
DE602005013793D1 (de) * 2004-07-27 2009-05-20 Astellas Pharma Inc Thiazolderivate mit vap-1-hemmender wirkung
WO2006010637A2 (en) * 2004-07-30 2006-02-02 Gpc Biotech Ag Pyridinylamines
EP1954696B1 (en) * 2005-01-19 2011-02-23 Bristol-Myers Squibb Company 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-amine derivatives and related compounds as p2y1 receptor inhibitors for the treatment of thromboembolic disorders
US8748627B2 (en) * 2006-02-15 2014-06-10 Abbvie Inc. Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
CA2641673A1 (en) * 2006-02-15 2007-08-23 Abbott Laboratories Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
US7928243B2 (en) * 2006-12-21 2011-04-19 Abbott Laboratories Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
AU2008287542C1 (en) * 2007-06-01 2015-01-22 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways

Also Published As

Publication number Publication date
CN101384568A (zh) 2009-03-11
WO2007095603A3 (en) 2008-03-13
US8735595B2 (en) 2014-05-27
CA2641766A1 (en) 2007-08-23
WO2007095603A2 (en) 2007-08-23
EP1991536A2 (en) 2008-11-19
US20070219251A1 (en) 2007-09-20
JP2009526868A (ja) 2009-07-23

Similar Documents

Publication Publication Date Title
CN101384568B (zh) 乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用
JP5291471B2 (ja) 新規なアセチル−ＣｏＡカルボキシラーゼ（ＡＣＣ）阻害薬およびこれらの糖尿病、肥満および代謝症候群における使用
US8748627B2 (en) Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
US7928243B2 (en) Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
WO2007019251A9 (en) Sphingosine kinase inhibitors and methods of their use
EP0934290B1 (fr) Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
WO2003080585A1 (en) Novel aminobenzamide derivative
HRP20040810A2 (en) Thiazole and oxazole derivatives that modulate ppar activity
CA2712962A1 (en) Thiazole derivative and use thereof as vap-1 inhibitor
ES2220504T3 (es) Derivados del aminotiazol y su uso como ligandos receptores de crf.
KR20100051812A (ko) 3-위치에서 이치환된 인돌-2-온 유도체, 그의 제조 및 그의 치료적 용도
JP5410969B2 (ja) ２，４，５−三置換チアゾール化合物、それを含有する医薬組成物、並びにその調製及び医学的使用
JP4550353B2 (ja) 造血器型プロスタグランジンｄ２合成酵素阻害剤
US20060178400A1 (en) Novel acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
MX2008010469A (en) Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
MX2008010471A (en) Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
WO1995018121A1 (en) Novel benzylamine derivative
MX2008010467A (en) Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
CN104245694A (zh) 具有治疗活性的氨基亚甲基吡唑啉酮
WO2002036547A1 (en) Cyclopropanecarboxylic acid amide compounds and medicinal use thereof
JPWO2006126581A1 (ja) 組合せ医薬

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: ABBVIE COMPANY

Free format text: FORMER OWNER: ABBOTT GMBH. + CO. KG

Effective date: 20130619

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20130619

Address after: Illinois State

Patentee after: ABBVIE company

Address before: Illinois State

Patentee before: Abbott GmbH. & Co. Kg

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20121212

Termination date: 20140215